Finding showed the inavolisib-based regimen reduced the risk of disease progression or death by 57% compared with palbociclib and fulvestrant alone. The Food and Drug Administration (FDA) has approved ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. PIK3CA mutations are frequently associated ...

Trastuzumab deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) with active CNS metastases: Real world data. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

The outlook for someone with PIK3CA-related overgrowth spectrum (PROS) depends on factors that vary from person to person. Early intervention and treatment can improve the outlook and prevent ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, ...

– The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and ...

– Approval is based on Phase III INAVO120 results, showing the Itovebi TM (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...

Enhertu plus Perjeta showed superior PFS compared to THP in HER2-positive advanced/metastatic breast cancer, irrespective of prior treatment, hormone receptor status, or PIK3CA mutations. Enhertu plus ...

In this MedPage Today video from the recent San Antonio Breast Cancer Symposium (SABCS), Gaia Griguolo, MD, of the Veneto Institute of Oncology in Padua, Italy, presents findings from a study ...

In this exclusive MedPage Today video, Virginia Kaklamani, MD, DSc, of UT Health Sciences Center in San Antonio and co-director of the San Antonio Breast Cancer Symposium (SABCS), discusses a subgroup ...